Table 4.
Characteristic between grade I-II HC vs. III-IV HC
| HC Grade I-II | HC Grade III-IV | P-value | |
|---|---|---|---|
| Gender | 0.39 | ||
| Male | 59 (64%) | 85 (70%) | |
| Female | 33 (36%) | 37 (30%) | |
| Source | 0.57 | ||
| M BM/PBSC | 32 (35%) | 43 (35%) | |
| MM BM/PBSC | 6 (7%) | 8 (7%) | |
| M UCB | 8 (9%) | 5 (4%) | |
| MM UCB | 46 (50%) | 66 (54%) | |
| Age Group | 0.27 | ||
| 0–20 | 48 (52%) | 56 (46%) | |
| 21–40 | 15 (16%) | 31 (25%) | |
| 41- | 29 (32%) | 35 (29%) | |
| Disease Risk | 0.23 | ||
| Non Malignant | 33 (36%) | 35 (29%) | |
| Standard Risk | 33 (36%) | 39 (32%) | |
| High Risk | 26 (28%) | 48 (39%) | |
| CMV | 0.50 | ||
| Positive | 4 (5%) | 8 (7%) | |
| Negative | 87 (96%) | 114 (93%) | |
| BK Virus | 0.46 | ||
| Positive | 37 (88%) | 60 (92%) | |
| Negative | 5 (12%) | 5 (8%) | |
| Conditioning | 0.77 | ||
| MAC: CY | 60 (65%) | 85 (70%) | |
| RIC: CY | 25 (27%) | 28 (23%) | |
| NO CY | 7 (8%) | 9 (7%) | |
| DAH | 0.20 | ||
| Yes | 2 (2%) | 7 (6%) | |
| No | 90 (97%) | 115 (94%) | |
Abbreviations: BM, bone marrow; CMV, cytomegalovirus; Cy, cyclophosphamide; DAH, diffuse alveolar hemorrhage; HC, hemorrhagic cystitis; M, matched; MAC, myeloablative conditioning; MM, mismatched; PBSC, peripheral blood stem cell; RIC, reduced-intensity conditioning; UCB, umbilical cord blood.